Tag: Business

• Free, one-hour, online panel discussion on key topics about power equipment maintenance and testing
• Experts from ASCO Power Technologies and Schneider Electric will address participants’ questions about benefits of, and tips for, upgrading existing transfer switches, load banks, and paralleling switchgear.

FLORHAM PARK, N.J. — (BUSINESS WIRE) –As part of its innovation webinar series, ASCO Power Technologies has announced its June 1 online panel discussion focusing on questions about power systems services and modernization. Sixty minutes in duration, Ask The Experts – Power System Services and Modernization is a live question-and-answer session that will be FREE to power industry professionals, engineers, facility managers, and technicians. Panelists from ASCO Power Technologies and Schneider Electric will discuss key topics and lessons-learned about servicing and upgrading power systems.

Reasons to Attend

By participating in the event, attendees will:

• Learn about the benefits of comprehensive periodic maintenance and testing for emergency power equipment and systems
• Understand NFPA 110 Requirements
• Participate in a question-and-answer session
• Earn PDH credits

About the Panelists

David Parker – Business Manager for Electrical Modernization Solutions, Schneider Electric

David Parker is a Business Development Manager within US Field Services at Schneider Electric. In the last 7 years, David has been focused on utilizing emerging technologies to improve performance and extend the service life of electrical distribution equipment.

Keith Negri – Business Development Manager for Electrical Modernization Solutions, Schneider Electric

Keith Negri is a Business Development Manager within US Field Services at Schneider Electric. For 35 years, he has provided customers with solutions for modernizing electrical distribution equipment in various industries.

Michael Maringola – Regional Service Director, ASCO Power Technologies

Michael has 18 years of experience in the electrical industry and has over 10 years of tenure with ASCO Power Technologies. Michael has held positions as Field Service Engineer and Service Sales Engineer and has led and supported a variety of power equipment modernization projects.

Keith Bassett – Regional Service Director, ASCO Power Technologies

Keith served in the United States Navy as a Gas Turbine Engine Electrician from 2001 to 2007. Keith started with ASCO Power Services as a Field Service Technician in 2007 and earned EGSA certification in 2008. He was nominated for Emerson’s Consider It Solved Award in 2008.

Matthew Miller – Business Development Manager, ASCO Power Technologies

As Business Development Manager, Matt is tasked with ensuring that ASCO offers the Service and Modernization solutions that its customers need, as well as developing practices for delivering solutions as a leader in the industry.

Registration Information

The event will be held at 11:00 AM Eastern Daylight Time on June 1, 2021. All interested professionals are encouraged to register now for this free online event by visiting www.ascopower.com.

About ASCO Power Technologies

ASCO Power Technologies has provided power reliability solutions for more than 125 years. The firm designs, manufactures, services, and supports automatic transfer switches, power control equipment, load banks, and critical power management systems. ASCO products serve mission-critical functions in data centers, healthcare facilities, telecommunication networks, commercial buildings, and industrial operations. To learn more about any of ASCO’s premium products and services, call (800) 800 ASCO (2726), email customercare@ascopower.com, or visit www.ascopower.com.

Contacts

Bhavesh Patel

+ 1 973 966 2746

Bhavesh.Patel@ascopower.com

Velodyne’s Solution Recognized for Enabling Transformative Smart Cities Projects

SAN JOSE, Calif. — (BUSINESS WIRE) — #VelodyneLidar—Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced its Intelligent Infrastructure Solution, powered by Bluecity, was named a winner of the 2021 Smart 50 Award, recognizing the solution’s innovation in smart city applications. The awards, presented by Smart Cities Connect, have a highly competitive review process and honor the 50 most transformative smart cities projects in the world.

Velodyne’s Intelligent Infrastructure Solution helps governments solve some of their most challenging and pervasive infrastructure problems. The solution combines Velodyne’s award-winning lidar sensors and Bluecity’s powerful artificial intelligence (AI) software to monitor traffic networks and public spaces. It generates real-time data analytics and predictions to improve traffic and crowd flow efficiency, advance sustainability and protect vulnerable road users.

The Intelligent Infrastructure Solution is deployed in multiple North America cities, including in Quebec and British Columbia, with upcoming installations in New Jersey. To qualify for a Smart 50 Award, solutions must have achieved results at a municipal scale or equivalent.

Velodyne’s Intelligent Infrastructure Solution creates a real-time 3D map of roads and intersections, providing precise traffic monitoring and analytics that is not possible with other types of sensors like cameras or radar. It reliably collects data in any lighting or weather condition, supporting 24/7, 365 days a year operation, while also protecting people’s privacy. The solution advances safety through multimodal analytics that detect various road users including vehicles, pedestrians and cyclists. It can predict, diagnose and address road safety challenges, helping municipalities and other customers make informed decisions to take corrective action.

“The Smart 50 Award recognizes Velodyne’s Intelligent Infrastructure Solution as one the 50 best examples of smart cities technology at work in the world,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “The award demonstrates how this innovative lidar-based approach can transform roads and transportation infrastructure into smart cities, creating sustainable, safer communities.”

The Smart 50 Awards Gala will be held in Washington, D.C. this October, co-located with Smart Cities Connect Conference.

About Velodyne Lidar

Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne, the global leader in lidar, is known for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.

Forward Looking Statements

This press release contains “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “can,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include uncertainties regarding government regulation and adoption of lidar, the uncertain impact of the COVID-19 pandemic on Velodyne’s and its customers’ businesses; Velodyne’s ability to manage growth; Velodyne’s ability to execute its business plan; uncertainties related to the ability of Velodyne’s customers to commercialize their products and the ultimate market acceptance of these products; the rate and degree of market acceptance of Velodyne’s products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne’s current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne’s intellectual property; and general economic and market conditions impacting demand for Velodyne’s products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Velodyne Investor Relations
InvestorRelations@velodyne.com

Media
Codeword

Liv Allen

velodyne@codeword.com

– Castor is supporting more than 250 COVID-19 studies in 40 countries across 1,750 hospitals

– Offers an expanded suite of tools and resources for clinical researchers in the fight against COVID-19 and other pandemic outbreaks

HOBOKEN, N.J. — (BUSINESS WIRE) — #COVID19—Castor, a leading provider of clinical trial technology to Democratize Clinical Research, announced today continued rapid adoption of its decentralized clinical trial platform to power COVID-19 studies globally.

At the start of the pandemic, Castor joined the global fight against the COVID-19 by offering its user-friendly, globally scalable Decentralized Clinical Trial (DCT) platform for free for all COVID-19 research projects. Castor is supporting more than 250 COVID-19 studies in 40 countries across 1,750 hospitals. 62,000 participants are enrolled in these trials and more than 139 Million data points have been captured. The company has also developed pre-built electronic case report forms (eCRFs) based on World Health Organization (WHO) standards, to help researchers start their study or registry in less than an hour, and saw emergency COVID projects go live within 6.5 days on average.

“When novel strains of viruses like the Coronavirus emerge, data is clearly our most valuable asset. Our research platform has been made available for hundreds of COVID-19 studies across the world. We are committed to supporting researchers to better understand the COVID-19 virus to develop life-saving therapies and vaccines, optimize valuable hospital resources and ultimately improve patient outcomes,” said Derk Arts, M.D., Chief Executive Officer, Castor. “We are providing free access to our EDC and DCT solutions as part of our commitment to empower researchers, remove barriers, streamline the clinical research process, and save lives.”

Examples of COVID-19 studies powered by Castor’s eClinical suite:

• World Health Organization’s Solidarity trial, the largest adaptive COVID-19 clinical trial ever conducted, with database support, adaptive randomization, and customized offline data capture. It is one of the largest international randomized trials for COVID-19 treatments, having currently enrolled over 13,000 patients in 500 hospital sites in over 30 countries.
• COVID-RED, the world’s first study to use machine learning in the diagnosis of COVID-19. This Takeda supported decentralized trial uses an app paired with the AVA wearable to monitor changes in vitals, attempting to alert participants to possible COVID infection before they show symptoms.
• Lucira Health chose Castor for its validation study of its PCR-quality molecular COVID test, which produces results in 30 minutes or less. The self-administered test, designed for easy use at home, has 98% accuracy compared to high sensitivity lab PCR tests, and was approved for emergency use in the fight against COVID-19.
• COVID-Predict, a machine learning study which aims to understand and predict which COVID-19 patients should receive which treatment and which type of care. This ensures the optimal allocation of limited hospital resources and makes certain the most high-risk COVID-19 patients receive the highest level of care. Castor’s Enterprise Tableau integration helped researchers clearly visualize each patient’s outcomes, comorbidities, and complications quickly and easily.

Click here to view over 250 COVID-19 studies running on Castor’s DCT platform that can help patients self-screen, enroll through a patient portal and remotely consent to COVID-19 studies.

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug and play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security and reusability of data for researchers worldwide. For more information, visit www.castoredc.com.

Contacts

Doug Weatherhead

Castor

doug.weatherhead@castoredc.com

Media

Kimberly Ha

KKH Advisors

kimberly.ha@kkhadvisors.com

– Company to report conclusions from its comprehensive strategic review, outline its updated business plan and report its fiscal year 2021 financial results

BEDMINSTER, N.J. — (BUSINESS WIRE) — TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs^tm), today announced that it will host a conference call and live video webcast on Thursday, June 10, 2021 at 5:00 PM ET. The Company will report its fiscal year 2021 financial results and provide a business update that same day.

As part of the event, the TYME executive management team will provide an updated business plan derived from the conclusions of the Company’s comprehensive strategic review that was conducted over the past several months. The goal of the strategic review was to assess TYME’s current pipeline, explore additional development opportunities, examine drug development process and determine how best to maximize the efficiency of the Company’s capital expenditures.

The call will be led by Richie Cunningham, Chief Executive Officer of TYME, who will present the findings of the strategic review. Mr. Cunningham will be joined by members of the executive management team, including the Company’s newly appointed Chief Financial Officer and Acting Chief Medical Officer, to answer questions. Interested participants and investors may access the conference call by dialing (866) 601-3896 (domestic) or (636) 812-6499 (international), Passcode: 3690369. The webcast will be accessible on the Events & Presentations page of the Investors section of the TYME website, tymeinc.com, and will be archived for 90 days following the event.

Following the Company’s presentation there will be a Q&A session. Management will address both live questions and those submitted in advance via email to TYME@jtcir.com. The deadline to submit questions for the conference call is 5:00 PM ET on June 8, 2021.

About TYME Technologies, Inc.

TYME Technologies, Inc. is an emerging biotechnology company developing cancer metabolism-based therapies that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and viruses such as COVID-19. For more information, visit www.tymeinc.com. Follow us on social media: Facebook, LinkedIn, Twitter, YouTube and Instagram.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates (including SM-88 and TYME- 18) and their clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned preclinical or clinical trials, including the proposed TYME-19 proof-of-concept study, preliminary data results and the therapeutic design and mechanisms of our drug candidates. The words “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” “anticipates,” and similar expressions (including their use in the negative) are intended to identify forward-looking statements. Forward-looking statements can also be identified by discussions of future matters such as: the effect of the novel coronavirus (COVID-19) pandemic and the associated impact on the national and global economy as well as impacts on the Company’s ongoing clinical trials and ability to analyze data from those trials; the cost of development and potential commercialization of our lead drug candidate and of other new products; expected releases of interim or final data from our clinical trials; possible collaborations; and the timing, scope, status, objectives and strategy of our ongoing and planned trials; the success of management transitions; and other statements that are not historical. The forward-looking statements contained in this press release are based on management’s current expectations and projections which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include but are not limited to: the severity, duration, and economic and operational impact of the COVID-19 pandemic; that the information is of a preliminary nature and may be subject to change; uncertainties inherent in the cost and outcomes of research and development, including the cost and availability of acceptable-quality clinical supply, and in the ability to achieve adequate start and completion dates, as well as uncertainties in clinical trial design and patient enrollment, dropout or discontinuation rates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final data from any clinical trials may differ from prior or preliminary study data; final results of additional clinical trials that may be different from the preliminary data analysis and may not support further clinical development; that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 or other drug candidates may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88 or other drug candidates; the ability of TYME and its collaborators to develop and realize collaborative synergies; competitive developments; and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on May 22, 2020 and its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 3, 2021 as well as subsequent reports we file from time to time with the U.S. Securities and Exchange Commission available at www.sec.gov.

The information contained in this press release is as of its release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.

Contacts

INVESTOR AND MEDIA CONTACT:
Jenene Thomas

JTC Team, LLC

833-475-8247

TYME@jtcir.com

CXone selected to modernize contact centers with numerous native digital channel options and seamless integration capabilities

HOBOKEN, N.J. — (BUSINESS WIRE) — #NICE—NICE CXone (Nasdaq: NICE) today announced one of the largest financial institutions in Latin America has chosen CXone, the industry’s most proven, complete and smart customer experience platform, for a comprehensive move of 10,000 agents to the cloud. It is phasing out an outdated on-premises system in favor of a more flexible, scalable option with CXone that is expected to drive down costs while improving customer and agent experiences.

The bank, classified by Forbes as one of the largest companies in the world based on business generated, assets and market cap, needed a true cloud environment to support its large contact center population of more than 30,000 agents. As it phases out its on-premises systems, the company is migrating 10,000 seats to CXone today with plans to fully transition to the cloud within the next three years. The financial services company pointed to CXone’s large number of application programming interfaces (APIs), comprehensive security and compliance standards on a single, proven platform and numerous native digital channel options as reasons for selecting the platform.

As an open platform, CXone provides hundreds of APIs and enables integrations with more than 100 partner solutions as well as customer-specific extensions, supporting a broad technology ecosystem that extends its capabilities. It also delivers protection for critical company data and supports compliance with global security regulations and privacy standards.

“Today’s customer experience economy calls for brands in all industries to elevate their game and catch up to next-generation consumer expectations,” said Paul Jarman, NICE CXone CEO. “Highly regulated financial institutions must remain compliant while also achieving exceptional levels of customer engagement in a mobile, on-demand digital environment. This win demonstrates what we’re seeing in the marketplace – accelerated adoption of CXone by organizations of all sizes that are realizing we are living through expedited cycles of technology innovation and adoption that require a new customer experience standard.”

Contact centers of all sizes are increasingly turning to NICE CXone to transform customer experiences based on its proven scalability, reliability, flexibility, and security. CXone enables integration with CRM or custom applications and supports rapid and ongoing innovation to differentiate service offerings. Customers who select NICE CXone are looking for a robust contact center solution to help them win in the experience economy by delivering exceptional customer and agent experiences that attract and retain customers and grow revenue. CXone’s unified cloud customer experience platform is helping businesses stay one step ahead with “smart” capabilities for infusing artificial intelligence and automation across the platform, agent experience and customer journey.

About NICE

NICE (Nasdaq: NICE) is the world’s leading provider of both cloud and on-premises enterprise software solutions that empower organizations to make smarter decisions based on advanced analytics of structured and unstructured data. NICE helps organizations of all sizes deliver better customer service, ensure compliance, combat fraud and safeguard citizens. Over 25,000 organizations in more than 150 countries, including over 85 of the Fortune 100 companies, are using NICE solutions. www.nice.com.

Trademark Note: NICE and the NICE logo are trademarks or registered trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE’s marks, please see: www.nice.com/nice-trademarks.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Jarman, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the “Company”). In some cases, such forward-looking statements can be identified by terms such as “believe,” “expect,” “seek,” “may,” “will,” “intend,” “should,” “project,” “anticipate,” “plan,” “estimate,” or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in economic and business conditions, including as a result of the COVID-19 pandemic; competition; successful execution of the Company’s growth strategy; success and growth of the Company’s cloud Software-as-a-Service business; changes in technology and market requirements; decline in demand for the Company’s products; inability to timely develop and introduce new technologies, products and applications; difficulties or delays in absorbing and integrating acquired operations, products, technologies and personnel; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company’s dependency on third-party cloud computing platform providers, hosting facilities and service partners;, cyber security attacks or other security breaches against the Company; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company’s reports filed from time to time with the SEC, including the Company’s Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.

Contacts

Corporate Media
Christopher Irwin-Dudek, +1 201 561 4442, chris.irwin-dudek@nice.com, ET

Investors
Marty Cohen, +1 551 256 5354, ir@nice.com, ET

Expanded R&D, engineering & design capabilities will complement suite of customer solutions

WALDWICK, N.J. — (BUSINESS WIRE) — NextPhase Medical Devices LLC, a leading provider of electronic manufacturing services (EMS) and single-use disposable devices to leading medical device OEMs, recently announced the acquisition of Proven Process Medical Devices Inc. Located in Mansfield, Mass., Proven Process expands NextPhase’s expertise in R&D, engineering, design and manufacturing of FDA Class II and III therapeutic and diagnostic devices. Proven Process’ areas of expertise include implantables, hand-held devices, combination devices, wearable devices and electro-mechanical capital equipment. Proven Process also adds a New England EMS Center of Excellence to NextPhase’s manufacturing locations in New Jersey, New Hampshire and Mexico.

NextPhase will incorporate Proven Process’ engineering expertise and design capabilities into its suite of customer solutions that will expand product offerings into high-growth categories, optimize supply chains and continue a culture of quality while also effectively managing costs.

“The acquisition of Proven Process reinforces NextPhase’s growth strategy, extends our technology platform and strengthens our capabilities to help our customers navigate medical device challenges,” said NextPhase CEO Carlo W. Colesanti. “Proven Process is known for its state-of-the-art engineering and its ability to act with speed to support customers in commercializing their technologies and products.”

Kenneth Fine, president of Proven Process, said, “Joining NextPhase will give our customers access to a world-class, Lean-focused organization with manufacturing capacity and scale. This will also help us to quickly expand our capabilities to better serve our customers. Our shared desire to engineer and manufacture some of the world’s most innovative medical devices that address unmet patient needs makes this a very exciting time for our two companies and for our employees and customers.”

About Proven Process Medical Devices

Proven Process is a medical device design, development and manufacturing services firm established by a tight-knit team in 1994 that envisioned a better way to serve the needs of medical device and healthcare brands and then set out to create it. More than two decades later, the company’s original vision has been realized, and is trusted by many of the medical device industry’s finest organizations. Proven Process’ extensive experience includes implantable, interventional, diagnostic and minimally invasive surgical devices. Learn more at www.provenprocess.com.

About NextPhase Medical Devices

NextPhase is a design, development and manufacturing partner that helps OEMs bring low- to medium-volume complex medical devices to market. Its expertise in electromechanical and single-use devices, combined with its skill in Lean manufacturing, helps it bring customer requirements to life. With an emphasis on its Core Values of customer priority, shop floor focus, teamwork, agility, accountability and continuous improvement, NextPhase has grown to become one of North America’s premier specialist outsourced manufacturers of medical devices. Learn more at www.nextphasemed.com.

Contacts

Robert Olsen

Chief Commercial Officer

sales@nextphasemed.com